
Psychedelic therapy represents a paradigm shift in mental health care, transitioning from daily symptom management to an interventional model that targets root causes. Unlike traditional psychopharmacology, this approach combines specific medicines with structured therapeutic support to access the unconscious mind, facilitating durable, long-lasting healing. Clinical research, particularly for treatment-resistant conditions like depression and moral injury in veterans, demonstrates that limited, guided exposures can lead to significant post-traumatic growth. While the sector attracts investor interest, success depends on navigating the complexities of FDA approval and the unique service-heavy delivery model. Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, emphasize that this evolution in care offers a pathway for patients to move beyond symptom suppression toward reclaiming their lives and contributing meaningfully to society.
Sign in to continue reading, translating and more.
Continue